Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation
Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Teva Pharmaceuticals,
Axsome shares jump as settlement will keep Teva's Auvelity generic off the market until 2038
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press release. Entrance of the generic will be delayed by an additional six months, until March 31, 2039, if Axsome gains an FDA pediatric exclusivity extension for its treatment.
Shares of Axsome Therapeutics ( AXSM 4.36%) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was ...
Axsome Therapeutics, Inc. (NASDAQ:AXSM) signed a settlement agreement with Teva Pharmaceuticals Inc (NYSE:TEVA). The ...
UBS analysts increased the price target on Axsome Therapeutics (NASDAQ:AXSM) shares to $133.00, up from the previous $105.00, while maintaining a Buy rating on the stock. The company, currently valued ...
BofA analyst Jason Gerberry raised the firm’s price target on Axsome Therapeutics (AXSM) to $167 from $143 and keeps a Buy rating on the shares ...
Under the agreement, Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted for Auvelity, or on or after ...
Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...
Shares of Axsome Therapeutics ( AXSM 20.22%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback